FDA Publishes RWE Landscape Analysis Covering Regulatory Decisions Across CDER, CBER, and CDRH Since 2011

The FDA's compiled landscape analysis of real-world evidence (RWE) use in regulatory decision-making signals a structural shift in how the Agency evaluates medical products across their full lifecycle, and regulatory affairs teams managing submissions through CDER, CBER, or CDRH should treat this publication as a working reference, not background reading.

The compilation documents instances since 2011 in which RWD-derived evidence informed regulatory outcomes across three categories: product approvals and authorizations, labeling changes, and assessments that concluded no regulatory action was warranted. The scope spans premarket authorization through post-market surveillance, covering New Drug Applications, Biologics License Applications, 510(k) notifications, and Premarket Approval submissions.

For CBER specifically, the analysis includes labeling changes tied to safety findings, drawing on both FDA-conducted and sponsor-conducted studies. Data sources referenced across the compilation include electronic health records, CMS claims data, Veterans Health Administration records, and adverse event monitoring systems, the same infrastructure that regulatory teams are increasingly expected to engage when designing post-approval commitments.

The practical read for regulatory affairs leads is in the breadth of decision types covered. RWE is no longer confined to post-market safety signaling; the Agency's own record shows it has been applied to premarket authorization decisions at CDRH and to effectiveness determinations at CDER. Teams building evidence packages for label expansions or REMS modifications should audit whether their RWD strategy aligns with the study designs reflected in this compilation.

The landscape analysis also functions as a transparency mechanism. By cataloguing the frequency and scope of RWE use across the Agency, FDA is establishing a documented baseline against which future guidance, including any updates to the existing RWE framework under the 21st Century Cures Act, will be measured. Regulatory leads tracking the evolution of substantial evidence standards should cross-reference this compilation against current ICH E8(R1) considerations for study design fit-for-purpose.

The next measurable checkpoint will be whether the frequency of RWE-supported decisions documented here accelerates in the post-2024 submission cohort, particularly for biologics labeling and device premarket pathways where real-world data infrastructure has matured most rapidly.

Source: FDA (Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health) via What's New: Vaccines, Blood & Biologics RSS Feed, June 3, 2026.